Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Neurocrine: Q1 Earnings Snapshot AP - Wed May 1, 6:18AM CDT

Neurocrine: Q1 Earnings Snapshot

NBIX : 142.29 (+0.27%)
Neurocrine: Q4 Earnings Snapshot AP - Wed Feb 7, 6:18AM CST

Neurocrine: Q4 Earnings Snapshot

NBIX : 142.29 (+0.27%)
Neurocrine: Q3 Earnings Snapshot AP - Tue Oct 31, 2023

Neurocrine: Q3 Earnings Snapshot

NBIX : 142.29 (+0.27%)
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results PR Newswire - Tue Oct 10, 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2023 financial results conference call and...

NBIX : 142.29 (+0.27%)
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints PR Newswire - Thu Oct 5, 2023

CAHtalyst™ Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children and...

NBIX : 142.29 (+0.27%)
Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023 PR Newswire - Thu Sep 21, 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the...

NBIX : 142.29 (+0.27%)
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation PR Newswire - Thu Sep 14, 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application...

NBIX : 142.29 (+0.27%)
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) PR Newswire - Tue Sep 12, 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data from the Phase 3 CAHtalyst™ Adult Study evaluating the...

NBIX : 142.29 (+0.27%)
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults PR Newswire - Mon Sep 11, 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the...

NBIX : 142.29 (+0.27%)
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September PR Newswire - Thu Aug 31, 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in September. Kyle Gano, Chief Business...

NBIX : 142.29 (+0.27%)

Barchart Exclusives

Nasdaq Market Has Perfect Bullish Historical Pattern – Don't Sell in May! Barchart - Sat May 18, 3:04PM CDT
"Sell in May and come back after Labor Day" is a well-known adage in the stock market that suggests investors should sell their stock holdings in May and return to the market after Labor Day in September. But, like so many market clichés, sayings that aren't supported by historical data are meaningless. An example is the upcoming Nasdaq seasonal buy with a perfect historical 15-year record. Will 2024 be the 16th year? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot